116 related articles for article (PubMed ID: 38219707)
1. Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics.
Stögbauer F; Otto R; Jöhrens K; Tinhofer I; Keilholz U; Poremba C; Keller U; Leser U; Weichert W; Boxberg M; Klinghammer K
Oral Oncol; 2024 Feb; 149():106678. PubMed ID: 38219707
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
Kogashiwa Y; Inoue H; Kuba K; Araki R; Yasuda M; Nakahira M; Sugasawa M
Head Neck; 2018 Nov; 40(11):2424-2431. PubMed ID: 30302873
[TBL] [Abstract][Full Text] [Related]
3. An Integrated Approach Identifies Mediators of Local Recurrence in Head and Neck Squamous Carcinoma.
Citron F; Armenia J; Franchin G; Polesel J; Talamini R; D'Andrea S; Sulfaro S; Croce CM; Klement W; Otasek D; Pastrello C; Tokar T; Jurisica I; French D; Bomben R; Vaccher E; Serraino D; Belletti B; Vecchione A; Barzan L; Baldassarre G
Clin Cancer Res; 2017 Jul; 23(14):3769-3780. PubMed ID: 28174235
[No Abstract] [Full Text] [Related]
4. Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma.
Li S; Wang Y; Sun R; Franceschi D; Pan H; Wei C; Ogbuehi AC; Lethaus B; Savkovic V; Gaus S; Zimmerer R; Ziebolz D; Schmalz G; Jiang X
J Immunol Res; 2022; 2022():2079389. PubMed ID: 36157879
[TBL] [Abstract][Full Text] [Related]
5. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Klinghammer K; Otto R; Raguse JD; Albers AE; Tinhofer I; Fichtner I; Leser U; Keilholz U; Hoffmann J
Int J Cancer; 2017 Sep; 141(6):1215-1221. PubMed ID: 28560858
[TBL] [Abstract][Full Text] [Related]
6. Therapy-Related Transcriptional Subtypes in Matched Primary and Recurrent Head and Neck Cancer.
Weber P; Künstner A; Hess J; Unger K; Marschner S; Idel C; Ribbat-Idel J; Baumeister P; Gires O; Walz C; Rietzler S; Valeanu L; Herkommer T; Kreutzer L; Klymenko O; Drexler G; Kirchner T; Maihöfer C; Ganswindt U; Walch A; Sterr M; Lickert H; Canis M; Rades D; Perner S; Berriel Diaz M; Herzig S; Lauber K; Wollenberg B; Busch H; Belka C; Zitzelsberger H
Clin Cancer Res; 2022 Mar; 28(5):1038-1052. PubMed ID: 34965946
[TBL] [Abstract][Full Text] [Related]
7. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
[TBL] [Abstract][Full Text] [Related]
8. Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
Lee DJ; Eun YG; Rho YS; Kim EH; Yim SY; Kang SH; Sohn BH; Kwon GH; Lee JS
Oral Oncol; 2018 Oct; 85():44-51. PubMed ID: 30220319
[TBL] [Abstract][Full Text] [Related]
9. Role of tumor budding and fibrotic cancer stroma in head and neck squamous cell carcinoma.
Mitha M; Aden D; Zaheer S; Alvi Y; Chintamani
Pathol Res Pract; 2024 Jan; 253():155052. PubMed ID: 38176309
[TBL] [Abstract][Full Text] [Related]
10. A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer.
Schinke H; Shi E; Lin Z; Quadt T; Kranz G; Zhou J; Wang H; Hess J; Heuer S; Belka C; Zitzelsberger H; Schumacher U; Genduso S; Riecken K; Gao Y; Wu Z; Reichel CA; Walz C; Canis M; Unger K; Baumeister P; Pan M; Gires O
Mol Cancer; 2022 Sep; 21(1):178. PubMed ID: 36076232
[TBL] [Abstract][Full Text] [Related]
11. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH
Ann Oncol; 2017 Oct; 28(10):2526-2532. PubMed ID: 28961833
[TBL] [Abstract][Full Text] [Related]
13. MiR-34a suppresses amphiregulin and tumor metastatic potential of head and neck squamous cell carcinoma (HNSCC).
Zhang J; Wang Y; Chen X; Zhou Y; Jiang F; Chen J; Wang L; Zhang WF
Oncotarget; 2015 Apr; 6(10):7454-69. PubMed ID: 25762634
[TBL] [Abstract][Full Text] [Related]
14. Immune landscape in molecular subtypes of human papillomavirus-negative head and neck cancer.
Xie M; Chaudhary R; Slebos RJC; Lee K; Song F; Poole MI; Hoening DS; Noel LC; Hernandez-Prera JC; Conejo-Garcia JR; Chung CH; Tan AC
Mol Carcinog; 2024 Jan; 63(1):120-135. PubMed ID: 37750589
[TBL] [Abstract][Full Text] [Related]
15. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
[TBL] [Abstract][Full Text] [Related]
17. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
18. HtrA3: a promising prognostic biomarker and therapeutic target for head and neck squamous cell carcinoma.
Chen Y; Yang J; Jin H; Wen W; Xu Y; Zhang X; Wang Y
PeerJ; 2023; 11():e16237. PubMed ID: 37842043
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Sacco AG; Cohen EE
J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
[TBL] [Abstract][Full Text] [Related]
20. Cancer associated fibroblast derived gene signature determines cancer subtypes and prognostic model construction in head and neck squamous cell carcinomas.
Wu S; Huang C; Su L; Wong PP; Huang Y; Chen R; Lin P; Ye Y; Song P; Han P; Huang X
Cancer Med; 2023 Mar; 12(5):6388-6400. PubMed ID: 36404634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
